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ment in 2007 compared to 2006 (39.81% vs.24.27%, p0.0002) and a non-significant
decline in 2008 (39.81% vs. 30.10%, p0.077). Non-Linear DID models showed that
MTM patients were more likely to meet the HbA1c criterion in 2007 (OR: 2.48, 95%
CI: 1.04-5.85, p0.038). Linear DID models for HbA1c showed a mean reduction of
0.54% (95% CI: 0.091%-0.98%, p0.018) for MTM patients. Among MTM patients,
rates of meeting HbA1c criterion in 2008 declined to baseline values.
CONCLUSIONS: Despite their greater complexity, optimal diabetes care signifi-
cantly improved among patients who were exposed to MTM. Drop in optimal
HbA1c control after discontinuation ofMTM exposure highlights the importance of
regular access to MTM services.
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OBJECTIVES:Tobacco control policies have focused on a combination of a variety of
initiatives such as monitoring, smoke-free public sites, cessation programmes,
health warnings, advertising bans and taxation. Smoking cessation treatments are
also recommended, as smokers who try to quit without help often fail in their
attempt.METHODS: TOSCA has been developed as an open or closed cohort semi-
Markov model, where current and former smokers may quit or relapse in their
smoking status over time. The impact of a tobacco policy on the quit rate is mod-
elled using the tobacco control scale (TCS) which has been shown to correlate with
quit ratios. Smoking prevalence, demographic inputs and mortality rates are de-
rived from published literature. The model predicts smoking prevalence, cumula-
tive smoking attributable deaths and morbidities over time (lung cancer, stroke,
coronary heart disease and chronic obstructive pulmonary disease). The impact of
tobacco control policies can be assessed over a 60 year horizon. RESULTS: Each one
point increase in TCS reduces smoking prevalence in both the open and closed
cohort model by 0.05% in absolute terms. This reduces cumulative smoking attrib-
utable mortality by 0.08% at 20 years and 0.13% at 60 years for lung cancer. Similar
results were obtained for stroke, COPD and CHD. For the UK this results in 10,069
and 8,908 fewer deaths in the open and closed cohort models respectively. Reduc-
tion in morbidities was slightly higher particularly for stroke where there was a
1.4% and 2.0% reduction in events at 20 and 60 years respectively. CONCLUSIONS:
Comprehensive smoking cessation policy is instrumental in reducing smoking
prevalence, mortality and morbidity. The TOSCAmodel can demonstrates the im-
pact of tobacco policy on smoking prevalence, mortality and morbidity for several
European countries.
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OBJECTIVES: The objective of this research was to examine differences in patterns
of statin prescribingbetween Northern Ireland and England both before and after
the introduction of the Quality and Outcomes Framework (QOF)METHODS:North-
ern Ireland practices were matched with practices in England, statin prescribing
data and QOF achievement scores (for the first year post-QOF) were obtained.
Crude prescribing data frommatched practicesweremanipulated to provide a data
set of Defined Daily Doses (DDDs)/1000 patients and cost/DDD/1000 patients for
each statin drug entity covering 1 year before and after the introduction of QOF.
QOF achievements were converted into percentage scores for matched practices.
Main outcome measure: Cost per defined daily dose (DDD) per 1,000 patients
RESULTS: Significantly less statins (DDD/1,000 patients) were dispensed in North-
ern Ireland comparedwith thematched region in England both before and after the
introduction of QOF (P 0.001). Significantly more statins, however, were dis-
pensed in both regions after the introduction of QOF. As a result of the introduction
of QOF, the cost/DDD/1000 patients rose by £13.17 in NI, but fell by £3.76 in the
matched region in England. CONCLUSIONS: Strategies should be considered to
educate prescribers on cost-effectiveness by increasing their awareness of the neg-
ative budgetary impact resulting from early adoption of new and expensive statins
and by encouraging generic prescribing.
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OBJECTIVES: In Ukraine cardiovascular diseases occupy a leading place in the
structure of death rate (25,9 %) and are one of most reasons of country depopula-
tion. From data of evidence-basedmedicine application of hypolipidemic prepara-
tions of statins in complex therapy of cardiovascular diseases and for the prophy-
laxis of their complications assists the decline of both common and cardiovascular
death rate. The aim of this research is a choice the optimal preparations from the
statins for the secondary prophylaxis of acute coronary syndrome on the basis of
cost-minimization analysis results in Ukraine. METHODS: Cost-minimization
analysis of hypolipidemic therapy with statins for the secondary prophylaxis of
acute coronary syndrome. The objects are results of a fewmeta-analyses andmul-
ticentral clinical trials: STELLAR, MERCURY, GREACE, 4S (Scandinavian Simvasta-
tin Survival Study); preparations of statins presented at the pharmaceuticalmarket
of Ukraine. The prices on preparations were taken from the price-lists (October,
2010). RESULTS: The analysis of meta-analyses and multicentral clinical trials re-
sults of atorvastatin, simvastatin and rosuvastatin preparations showed that these
preparations have practically equal clinical effectiveness for the secondary pro-
phylaxis of acute coronary syndrome. The results of cost-minimization analysis
showed that the costs for preparations of atorvastatin were less than the costs for
preparations of simvastatin and rosuvastatin. The hypolipidemic therapy with
rosuvastatin are the most expensive. The costs for the course of prophylaxis by
preparations of simvastatin are less, than the costs for the course of prophylaxis by
rosuvastatin and more, than the costs for prophylaxis by atorvastatin.
CONCLUSIONS: Generic preparations of atorvastatin are the least expense among
others statins presented at the pharmaceutical market of Ukraine, and remain
preparations of choice for the prophylaxis of acute coronary syndrome.
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OBJECTIVES: To assess the impact of receiving emotional support on self-per-
ceived current health status and physical and mental health wellness among
adults with cardiovascular disorders (CVD) in the United States. METHODS: We
identified adults aged 40 years with CVD (i.e., self-reported stroke, congestive
heart failure, coronary heart disease or heart attack) in the 2007-2008 National
Health and Nutrition Examination Survey (NHANES), a nationally representative
survey of the non-institutionalized US population. Outcome measures including
self-reported current health status (poor [fair/poor] vs. good [good/very good/ex-
cellent]), days with poor physical health, days with poor mental health, and inac-
tive days due to poor physical/mental health, were compared between CVD pa-
tients receiving and not receiving emotional support using appropriate univariate
tests. All analyses were stratified by patient demographics, including gender and
race. National estimates were obtained using sample weights. RESULTS: In 2007-
2008, 12.4% (Population Estimate16.6 million; 95% CI: 14.2-19.0 million) of the US
population40 years of age had self-reported CVD, of which92% denoted having
someone (e.g., spouse, neighbor) provide emotional support, with the proportion
greater among females thanmales (93.7% vs. 89.8%; P0.188). Among CVD patients
not receiving emotional support, a greater proportion reported current health sta-
tus as ‘poor’ compared with patients receiving emotional support (51.2% vs. 34.6%;
P0.091). Similarly, compared with CVD patients receiving emotional support, the
number of dayswith poor physical health (6.9 vs. 12.3 days; P0.014),mental health
(4.4 vs. 7.8 days; P0.137), and inactive days (4.4 vs. 9.5 days; P0.101) were each2
times greater among patients not receiving emotional support. CONCLUSIONS: A
majority patients with CVD diagnosis reported receiving some emotional support,
with receipt of emotional support being associated with improved health status.
Health care providers (e.g., physicians, pharmacists) should emphasize the value of
emotional support to patientswith CVD,whichmay help in improving the physical
and mental well-being of these patients.
PCV112
THE FOCUS ON CARDIOVASCULAR DRUGS IN WORKS OF AGENCY FOR HEALTH
TECHNOLOGY ASSESSMENT IN POLAND (AOTM) IN YEARS 2005-2011 AS AN
EXAMPLE OF A LIGHT TOUCH HTA AGENCY
Ofierska-Sujkowska G, Jagodzinska-Kalinowska K, Matusewicz W, Pasierski T
Agency for Health Technology Assessment in Poland (AHTAPol), Warsaw, Poland
OBJECTIVES: The objective of this study is to assess scope and role of drug thera-
pies in cardiology/vascular diseases in AOTM works. AOTM is one of a light touch
HTA Agencies around the world with respect to drugs evaluation before desion-
taking on reimbursement and pricing. AOTM stands for quality assurance of HTA
reports developed by industry applying for inclusion of drugs to BBP (basic benefit
package). It deals also with appraisal of submitted evidence. AOTM does not de-
velop HTA reports from the scratch with respect to drugs. Therefore no priority
setting process is needed and no bias in selection of topics for assessment should
be in place.METHODS:Among recommendations of AOTMpublished until the end
of 2011 we analyzed all related to cardiovascular drugs. RESULTS: Among 400
AOTM decisions verified only 31 (8%) were related to cardiovascular drugs. Recom-
mendation regarding non–drug technologies were issued to 47 (12%) of 400 tech-
nologies. 58 (15%) applied to drugs used in the treatment of nervous disorders, 34
(9%) metabolic disorders, 21 (5%) genito-urinary system. The largest number (142/
36% of 400) of analyzed submission was connected with antineoplastic and immu-
nomodulating agents; 105 (74%) of them regarding oncology treatment. Fifteen
percent of verified docummentations applied to other, single indications.
CONCLUSIONS: The influence of cardiovascular drugs for AOTM recommendations
were not significant and no bias with respect to special focus on cardiovascular drugs
has been observed in comparision to focus on other medicines. Most of commissions
prepared by AOTM were related to antineoplastic (cancer chemotherapy) treatment
representing normal trends in research and development in medicine.
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